Elagolix Pharmacokinetic Profiles in Women With Renal or Hepatic Impairment

Ng J, Juki Ng, Duan WR, W. Rachel Duan, Marbury T, Thomas Marbury, Schmidt JM, Jeffrey M. Schmidt, Klein CE, Cheri E. Klein
Clinical pharmacology in drug development · 2018 · vol. 8(8) , pp. 1053–1061 · doi:10.1002/cpdd.640 · PMID:30570832 · W2906559481
article OA: closed CC0 ⤵ 11 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-08 ⓘ

Elagolix exposure was similar in women with normal and impaired renal function, similar in mild hepatic impairment, but increased significantly with moderate and severe hepatic impairment.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

The aim of these studies was to assess the safety and pharmacokinetics of elagolix, an oral nonpeptide gonadotropin-releasing hormone antagonist following oral administration in women with renal or hepatic impairment. Two phase 1 studies were conducted in adult women with normal renal function versus renal impairment (reduced study), and normal hepatic function versus hepatic impairment (full study design). All women received a single dose of elagolix 200 mg (renal) or 150 mg (hepatic). Intensive pharmacokinetic blood samples were collected. Elagolix exposures were comparable in women with normal renal function and those with moderate/severe renal impairment or end-stage renal disease. Elagolix exposures also appeared to be similar in women with normal hepatic function and women with mild hepatic impairment. Elagolix area under the curve in women with moderate hepatic impairment and with severe hepatic impairment was approximately 3-fold and 7-fold higher than in women with normal hepatic function. The adverse event incidence was low, with the main events being mild nausea and headache. No dosage adjustment was needed in women with renal impairment or women with mild hepatic impairment. Although an elagolix dose of 150 mg once daily may be used in women with moderate hepatic impairment for up to 6 months, this elagolix dose should not be used in women with severe hepatic impairment.

My notes (saved in your browser only)

MeSH descriptors

Gonadotropin-Releasing Hormone Hormone Antagonists Hydrocarbons, Fluorinated Kidney Diseases Liver Diseases Pyrimidines Administration, Oral Adolescent Adult Area Under Curve Dose-Response Relationship, Drug Female Glomerular Filtration Rate Gonadotropin-Releasing Hormone Hormone Antagonists Hormone Antagonists Hormone Antagonists Hormone Antagonists Humans Hydrocarbons, Fluorinated

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (8)

Cited by (12)

Source provenance

europepmc
last seen: 2026-08-16T09:21:09.727480+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:19:25.021412+00:00
License: CC0 · commercial use OK